Posted by Michael Wonder on 18 Apr 2024
FDA approves Genentech's Alecensa as first adjuvant treatment for people with ALK positive early stage lung cancer
18 April 2024 - Approval based on Phase 3 ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK positive early stage resected non-small cell lung cancer.
Genentech announced today that the US FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase positive non-small cell lung cancer (tumours ≥ 4 cm or node positive), as detected by an FDA approved test.
